Dolutegravir monotherapy: an option for highly adherent HIV1-infected naive patients with relatively low zenith HIV-RNA?

Massimiliano LanzafameDiagnosis and Therapy of HIV Infection Unit, G.B. Rossi University Hospital, Verona, Italy; Correspondence[email protected]

Sebastiano RizzardoInfectious Diseases Unit, G.B. Rossi University Hospital, Verona, Italy;

Daniela PiacentiniInfectious Diseases Unit, G.B. Rossi University Hospital, Verona, Italy;

Emanuela LattuadaInfectious Diseases Unit, G.B. Rossi University Hospital, Verona, Italy;

Sheila ChiesiDepartment of Medicine, School of Medicine, Nazarbayev University, Astana, Kazakhstan;;

Sandro VentoUniversity Medical Center, Astana, Kazakhstan

References

Eriksen J, Albert J, Blaxhult A, et al. Antiretroviral treatment for HIV infection: Swedish recommendationss 2016. Infect Dis. 2017;49:1–34.
PubMed Web of Science ®Google Scholar
Lanzafame M, Piacentini D, Lattuada E, et al. “High” antiretroviral deintensification, a strategy to avoid drug interactions and unfavourable long-term effects of HAART. Infect Dis. 2018;1–3. DOI: 10.1080/23744235.2018.1482420 (Epub ahead of print).
PubMed Web of Science ®Google Scholar
Blanco JL, Marcelin AG, Katlama C, et al. Dolutegravir resistance mutations: lessons from monotherapy studies. Curr Opin Infect Dis. 2018;31:237–245.
PubMed Web of Science ®Google Scholar
Lanzafame M, Nicolè S, Gibellini D, et al. Dolutegravir monotherapy in HIV-infected naive patients with an HIV-RNA load <100 000 copies/mL: a medium-term follow-up. J Antimicrob Chemother. 2017;72:2136–2138.
PubMed Web of Science ®Google Scholar
Italian Cohort Naive Antiretrovirals (ICONA) Foundation cohort report: [Internet] Update June 2016; [cited 2018 Jul 20]. Available from: www.fsk.it/download/allegato3reporticonagiugno2016.pdf.
Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Dolutegravir monotherapy: an option for highly adherent HIV1-infected naive patients with relatively low zenith HIV-RNA?

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Dolutegravir monotherapy: an option for highly adherent HIV1-infected naive patients with relatively low zenith HIV-RNA?

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date